四環生物(000518.SZ):許琦等人信披違規案違法事實不成立 證監會決定結案
格隆匯5月12日丨四環生物(000518.SZ)公佈,公司於2019年1月7日收到中國證監會送達的《調查通知書》(稽總調查字190059號)。因公司涉嫌信息披露違法違規,根據《中華人民共和國證券法》的有關規定,中國證監會決定對公司立案調查。2019年9月19日,公司及相關當事人收到中國證監會下發的《行政處罰及市場禁入事先告知書》([2019]135號)。
近日,相關當事人收到中國證監會下發的《結案通知書》(結案字[2020]31、32、33、37、40號),現將主要內容公告如下:經審理,許琦、徐衞球、林梅、廖述斌、李忠國的涉案違法事實不成立,我會決定本案結案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.